{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.4","upperLimit":"31.4","value":"15.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"PFS is defined as time from first dose of study treatment to progression or death due to any cause, based on modified European Society for Bone and Marrow Transplantation (EBMT) criteria per Investigator's assessment","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.","id":"OG000","title":"LBH589 + Bortezomib + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"FAS: The FAS comprised of all subjects who took at least one dose of any study treatment component.","reportingStatus":"POSTED","timeFrame":"duration of study up to approx. 4 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}